Triple-negative breast cancer: Current perspective on the evolving therapeutic landscape

Joe Mehanna; Fady G.H. Haddad; Roland Eid; Matteo Lambertini; Hampig Raphael Kourie

doi:10.2147/IJWH.S178349

Triple-negative breast cancer: Current perspective on the evolving therapeutic landscape

Joe Mehanna, Fady G.H. Haddad, Roland Eid, Matteo Lambertini, Hampig Raphael Kourie

Research output: Contribution to journal › Review article › peer-review

107 Scopus citations

Abstract

Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited treatment options, namely chemotherapy. Different molecular studies have recently classified TNBC into different subtypes opening the door to potential new-targeted treatment options. In this review, we discuss the current standard of care in the treatment of TNBC in the neoadjuvant, adjuvant and metastatic settings. In addition, we summarize the ongoing phase III clinical trials evaluating different associations between the 3 pillars of anticancer treatment: chemotherapy, targeted therapy and immunotherapy.

Original language	English (US)
Pages (from-to)	431-437
Number of pages	7
Journal	International Journal of Women's Health
Volume	11
DOIs	https://doi.org/10.2147/IJWH.S178349
State	Published - 2019
Externally published	Yes

Keywords

Breast cancer
Immunotherapy
PARP inhibitors
Triple-negative

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology
Maternity and Midwifery

Access to Document

10.2147/IJWH.S178349

Cite this

@article{e8763429d688471f9ec3fcedda856226,

title = "Triple-negative breast cancer: Current perspective on the evolving therapeutic landscape",

abstract = "Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited treatment options, namely chemotherapy. Different molecular studies have recently classified TNBC into different subtypes opening the door to potential new-targeted treatment options. In this review, we discuss the current standard of care in the treatment of TNBC in the neoadjuvant, adjuvant and metastatic settings. In addition, we summarize the ongoing phase III clinical trials evaluating different associations between the 3 pillars of anticancer treatment: chemotherapy, targeted therapy and immunotherapy.",

keywords = "Breast cancer, Immunotherapy, PARP inhibitors, Triple-negative",

author = "Joe Mehanna and Haddad, {Fady G.H.} and Roland Eid and Matteo Lambertini and Kourie, {Hampig Raphael}",

note = "Publisher Copyright: {\textcopyright} 2019 Mehanna et al.",

year = "2019",

doi = "10.2147/IJWH.S178349",

language = "English (US)",

volume = "11",

pages = "431--437",

journal = "International Journal of Women's Health",

issn = "1179-1411",

publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Triple-negative breast cancer

T2 - Current perspective on the evolving therapeutic landscape

AU - Mehanna, Joe

AU - Haddad, Fady G.H.

AU - Eid, Roland

AU - Lambertini, Matteo

AU - Kourie, Hampig Raphael

PY - 2019

Y1 - 2019

N2 - Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited treatment options, namely chemotherapy. Different molecular studies have recently classified TNBC into different subtypes opening the door to potential new-targeted treatment options. In this review, we discuss the current standard of care in the treatment of TNBC in the neoadjuvant, adjuvant and metastatic settings. In addition, we summarize the ongoing phase III clinical trials evaluating different associations between the 3 pillars of anticancer treatment: chemotherapy, targeted therapy and immunotherapy.

AB - Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited treatment options, namely chemotherapy. Different molecular studies have recently classified TNBC into different subtypes opening the door to potential new-targeted treatment options. In this review, we discuss the current standard of care in the treatment of TNBC in the neoadjuvant, adjuvant and metastatic settings. In addition, we summarize the ongoing phase III clinical trials evaluating different associations between the 3 pillars of anticancer treatment: chemotherapy, targeted therapy and immunotherapy.

KW - Breast cancer

KW - Immunotherapy

KW - PARP inhibitors

KW - Triple-negative

UR - http://www.scopus.com/inward/record.url?scp=85070221076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070221076&partnerID=8YFLogxK

U2 - 10.2147/IJWH.S178349

DO - 10.2147/IJWH.S178349

M3 - Review article

C2 - 31447592

AN - SCOPUS:85070221076

SN - 1179-1411

VL - 11

SP - 431

EP - 437

JO - International Journal of Women's Health

JF - International Journal of Women's Health

ER -

Triple-negative breast cancer: Current perspective on the evolving therapeutic landscape

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this